<DOC>
	<DOCNO>NCT02360657</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability effect JNJ-54861911 level amyloid-beta Cerebrospinal Fluid ( CSF ) plasma follow 4 week treatment Japanese participant asymptomatic risk Alzheimer Dementia ( ARAD ) intend target dose range .</brief_summary>
	<brief_title>Study Investigating Effects JNJ-54861911 Amyloid-beta Processing Cerebrospinal Fluid ( CSF ) Plasma Japanese Participants Asymptomatic Risk Alzheimer Dementia</brief_title>
	<detailed_description>This multi-center ( one hospital medical school team work medical research study ) , double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( experimental treatment procedure compare inactive substance ) , randomize ( study medication assign chance ) , multiple dose , Proof Mechanism ( POM ) study Japanese participant ARAD . All eligible participant randomly assign 1 3 treatment group ( , placebo , JNJ-54861911 10 milligram [ mg ] JNJ-54861911 50 mg daily regimen ) . This study consist Screening Phase ( 8-week ) , Double blind Treatment Phase ( 4-week ) , Follow-up Phase ( 2-week ) . The maximum study duration participant 14 week . Participant 's safety monitor throughout study .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Participant must sufficient education work experience exclude mental retardation base Diagnostic Statistical Manual Mental Disorders 4th edition , Text Revision ( DSMIVTR ) must able read write must adequate hear visual acuity complete require psychometric test Participant must Clinical Dementia Rating Scale Japanese version ( CDRJ ) score ' 0 ' rat normal Participant must evidence amyloid deposition demonstrate low Cerebrospinal Fluid ( CSF ) Amyloid ( A ) beta 142 level Screening Participant must body mass index 18 35 kilogram per square meter , inclusive , Screening Participant must otherwise healthy age group medically stable without medication basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening Baseline Participant evidence brain disease potential early sign Alzheimer 's disease ( AD ) typical age relate change , abnormality could explain possible cognitive deficit Participant diagnose dementia due AD , due disease , AD contribution disorder ( mixed dementia ) Participant evidence familial autosomal dominant AD Participant contraindication Magnetic Resonance Imaging ( MRI ) ( example , prosthesis , implant , claustrophobia , pacemaker , others ) Participant clinically significant abnormal physical neurological examination , vital sign 12lead ECG ( include QTc great 450 millisecond male female , leave bundle branch block , atrioventricular [ AV ] block second degree high , permanent pacemaker implantable cardioverter defibrillator [ ICD ] ) Screening Baseline , opinion investigator appropriate reasonable population study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Alzheimer Dementia</keyword>
	<keyword>JNJ-54861911</keyword>
	<keyword>Beta Secretase Inhibitor</keyword>
</DOC>